NASDAQ:EYPT Eyepoint Pharmaceuticals Q3 2024 Earnings Report $3.62 -0.03 (-0.82%) Closing price 09/25/2026 04:00 PM EasternExtended Trading$3.62 0.00 (-0.14%) As of 09/25/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Eyepoint Pharmaceuticals EPS ResultsActual EPS-$0.54Consensus EPS -$0.48Beat/MissMissed by -$0.06One Year Ago EPSN/AEyepoint Pharmaceuticals Revenue ResultsActual Revenue$10.52 millionExpected Revenue$12.35 millionBeat/MissMissed by -$1.83 millionYoY Revenue GrowthN/AEyepoint Pharmaceuticals Announcement DetailsQuarterQ3 2024Date11/7/2024TimeBefore Market OpensConference Call DateThursday, November 7, 2024Conference Call Time7:00AM ETUpcoming EarningsEyepoint Pharmaceuticals' Q3 2026 earnings is estimated for Wednesday, November 4, 2026, based on past reporting schedules, with a conference call scheduled at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Eyepoint Pharmaceuticals Earnings HeadlinesEyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Rating Upgraded by Wall Street ZenSeptember 27 at 1:07 AM | americanbankingnews.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPTSeptember 24 at 5:34 PM | prnewswire.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.September 27 at 1:00 AM | Stansberry Research (Ad)INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPTSeptember 22, 2026 | globenewswire.comEyepoint Pharmaceuticals (NASDAQ:EYPT) Downgraded to Strong Sell Rating by Wall Street ZenSeptember 19, 2026 | americanbankingnews.comContrasting Bristol Myers Squibb (NYSE:BMY) and Eyepoint Pharmaceuticals (NASDAQ:EYPT)September 18, 2026 | americanbankingnews.comSee More Eyepoint Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Eyepoint Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eyepoint Pharmaceuticals and other key companies, straight to your email. Email Address About Eyepoint PharmaceuticalsEyepoint Pharmaceuticals (NASDAQ:EYPT) is a commercial-stage biotechnology company focused on developing and delivering treatments for serious eye diseases. The company’s proprietary technology is designed to provide sustained, localized release of pharmaceutical compounds within the eye, with the goal of reducing treatment frequency and improving outcomes for patients and physicians. EyePoint’s commercial products include YUTIQ, an injectable fluocinolone acetonide implant for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye, and DEXYCU, a sustained-release dexamethasone intraocular suspension used to treat inflammation following ophthalmic surgery. The products are marketed in the United States. The company’s pipeline includes investigational sustained-release therapies for retinal diseases. Its lead development program, EYP-1901, is an intravitreal formulation of vorolanib being evaluated for conditions including wet age-related macular degeneration and diabetic retinopathy. EyePoint was formerly known as pSivida Corp. and adopted the EyePoint Pharmaceuticals name in 2018. The company is headquartered in Watertown, Massachusetts.View Eyepoint Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/21 - 09/25Costco Ends Its Fiscal Year on a High Note, Eyes Big ExpansionCracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic Problem5 Scary-Good Stocks With Strong October Catalysts and Breakout PotentialDarden Restaurants Serves Up Fresh Catalysts for a Stock Price RallySoFi Is Bypassing the Banking Bottleneck With Stablecoin SettlementSuper Micro’s Vera Rubin Shipments Put Its AI Infrastructure Advantage to the Test Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
